Results 171 to 180 of about 86,485 (257)

Beyond the Heart‐Lung Axis: A Review of the Crosstalk Between the Hemodynamic, Neurohormonal, and Immune Systems in Pulmonary Hypertension

Comprehensive Physiology, Volume 16, Issue 5, October 2026.
Pulmonary hypertension is driven by dynamic crosstalk beyond the physical connection between the heart and lung, involving neurohormonal systems, immune pathways, and peripheral organs. This review highlights how multisystem signaling contributes to disease progression and may reveal new diagnostic and therapeutic targets.
Alejandro A. Vega, Juliet M. Alfaro, David S. Pinto, Maryam Emamimeybodi, Soban Umar   +4 more
wiley   +1 more source

Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma. [PDF]

Am J Hematol
McElwee J, Elsey G, Gonzalez R, Julian K, Snyder J, Granger K, Rice M, Nachar VR, Atrash S, Hansen DK, Grajales-Cruz A, Cahoon C, Bryan B, Sborov D, Mahmoudjafari Z, Warrick M, Dominick A, Rudoni J, Kissam J, Vince M, Khouri J, Ahmed I, Pianko M, Moore DC, Davis JA.   +24 more
europepmc   +1 more source

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

Clinical Pharmacology &Therapeutics, Volume 120, Issue 4, Page 1027-1040, October 2026.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin, Martin Bergstrand, Ana Ruiz‐Garcia, Simone Filosto, Rhine Shen   +4 more
wiley   +1 more source

Comparative Effects of Sertraline, Methotrexate, and Biologic Therapies on Circulating Inflammatory and Neurotrophic Mediators and Striatal Gene Expression in Collagen-Induced Arthritis. [PDF]

Int J Mol Sci
Chmielewski G, Mikiewicz M, Kuna J, Jaśkiewicz Ł, Czerwińska J, Wróbel M, Kaczorek-Łukowska E, Majewski MS, Krajewska-Włodarczyk M.   +8 more
europepmc   +1 more source

The Sleeping Giant: Metabolism and Autophagy in the Generation and Survival of Dormant Polyploid Giant Cancer Cells

MedComm, Volume 7, Issue 10, October 2026.
Polyploid giant cancer cells (PGCCs) arise in response to stress and play a critical role in therapy resistance and tumor dormancy. These cells can evade conventional treatments and later contribute to cancer relapse by generating progeny through nonmitotic, amitotic mechanisms.
Silvia Guil‐Luna, María Teresa Sánchez‐Montero, Alejandra Díaz‐Chacón, Antonio Rodríguez‐Ariza   +3 more
wiley   +1 more source

Tocilizumab Treatment in Refractory Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Case Report and Literature Review. [PDF]

J Inflamm Res
Lin X, Zhou S, Zhang Z, Zhu S, Quan Y, Peng J, He H.   +6 more
europepmc   +1 more source

Neutrophil Extracellular Traps in Atherosclerosis and Cardiovascular Disease

MedComm, Volume 7, Issue 10, October 2026.
NETs as integrated effectors in the atherosclerotic cardiovascular disease continuum. Activated neutrophils release NETs that promote endothelial injury, thrombo‐inflammation, and plaque destabilization throughout atherosclerotic disease progression. Created with BioRender.com.
Ji Zhang, Fangjiaqi Wei, Mengdi Qu, Yuwen Shao, Tingye Xu, Darko Stojkov, Hans‐Uwe Simon, Ben Huang, Changhong Miao, Hao Zhang   +9 more
wiley   +1 more source

Interleukin-6 Inhibition for Patients with Acute Myocardial Infarction: <i>A Systematic Review and Meta-Analysis</i>. [PDF]

Saudi Med J
Alasmary MY, Almalki MJ, Almalki FH, Khubzan WD, Rajab MH, Almalki MS, Almalki HA, Alsuwat OM, Alghannami HM.   +8 more
europepmc   +1 more source

Drug‐Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Tocilizumab is an interleukin‐6 (IL‐6) receptor antagonist indicated for various rheumatologic conditions. While hepatotoxicity is a recognized adverse effect, it predominantly manifests as hepatocellular injury. We report a rare case of drug‐induced liver injury (DILI) presenting with a cholestatic pattern and cholangitis features in a 75 ...
Louis‐Edmond Barbaro, Nouha Ben Othman, Delphine Viard, Fanny Rocher, Elliot Ewig, Raja Mroue, Claire Amigues, Alexandre O. Gérard   +7 more
wiley   +1 more source

Interleukin-6 levels decrease following rituximab treatment but increase following tocilizumab treatment. [PDF]

Ann Hematol
Ide M, Fukumoto T, Ohnishi H, Okamura S, Kawano K, Yokoyama T, Kameda T.   +6 more
europepmc   +1 more source